Science News
from research organizations

New prognostic factor for early breast adenocarcinoma

Date:
March 25, 2010
Source:
American Journal of Pathology
Summary:
Scientists have discovered that high expression levels of delta-like ligand 4 (DLL4) predict poor prognosis in breast cancer.
Share:
       
FULL STORY

Dr. Adrian L. Harris and colleagues at the Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK have discovered that high expression levels of delta-like ligand 4 (DLL4) predict poor prognosis in breast cancer.

They present these findings in the April 2010 issue of the American Journal of Pathology.

Survival of patients with breast cancer is dependent on cancer stage, aggressiveness, and genetic makeup. New diagnostic markers that predict prognosis would therefore aid in therapeutic decision-making.

DLL4, a cell-signalling molecule expressed on endothelial cells, is regulated by the therapeutic target VEGF (vascular endothelial growth factor) as well as by low oxygen levels, suggesting that it plays possible roles in new blood vessel formation and growth in tumors. To explore the role of DLL4 in breast cancer, Jubb et al examined breast adenocarcinomas, normal breast tissues, and angiosarcomas. They found that DLL4 was expressed in endothelial cells within the tumor proper of breast adenocarcinomas, but not in normal non-lactating breast tissue, and that high expression levels of DLL4 predicted poor prognosis regarding both overall and relapse-free survival. Assessing which patients express DLL4 may therefore may be used to predict patients' responsiveness to anti-VEGF therapies.

Dr. Harris and colleagues "suggest that tumor endothelial expression of Dll4 is a significant prognostic factor in early breast adenocarcinoma." They believe "these data may have clinical relevance, as preclinical models suggest that assessing which patients express Dll4 in their tumor endothelium may be critical in predicting benefit from anti-VEGF therapies."

Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li J-L, Allen P, Leek R, Noguera-Troise I, Gatter KC, Thurston G, Harris AL: Expression of Vascular Notch Ligand Delta-like 4 (Dll4) and Inflammatory Markers in Breast Cancer. Am J Pathol 2010 176, 2019-2028


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Cite This Page:

American Journal of Pathology. "New prognostic factor for early breast adenocarcinoma." ScienceDaily. ScienceDaily, 25 March 2010. <www.sciencedaily.com/releases/2010/03/100325225519.htm>.
American Journal of Pathology. (2010, March 25). New prognostic factor for early breast adenocarcinoma. ScienceDaily. Retrieved May 25, 2015 from www.sciencedaily.com/releases/2010/03/100325225519.htm
American Journal of Pathology. "New prognostic factor for early breast adenocarcinoma." ScienceDaily. www.sciencedaily.com/releases/2010/03/100325225519.htm (accessed May 25, 2015).

Share This Page: